Global Retirement Partners LLC Has $768,000 Stock Position in Novo Nordisk A/S $NVO

Global Retirement Partners LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 51.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,840 shares of the company’s stock after selling 14,854 shares during the period. Global Retirement Partners LLC’s holdings in Novo Nordisk A/S were worth $768,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. True Wealth Design LLC lifted its position in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares in the last quarter. NewSquare Capital LLC grew its position in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $37,000. State of Wyoming purchased a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $38,000. Finally, Maseco LLP purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $39,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. Finally, Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $57.34 on Friday. The business’s 50-day simple moving average is $49.47 and its 200-day simple moving average is $55.47. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The firm has a market cap of $256.02 billion, a price-to-earnings ratio of 16.67 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.